Xanthine oxidase-IN-21 

Xanthine oxidase-IN-21, a Genipin (HY-17389) derivative, is an orally active mixed competitive xanthine oxidase (XOD) inhibitor with an IC₅₀ of 0.68 μM. Xanthine oxidase-IN-21 reduces renal fibrosis by decreasing α-SMA expression and suppresses pro-inflammatory cytokines IL-1β, IL-6, and TNF-α through NF-κB pathway regulation. Xanthine oxidase-IN-21 also inhibits URAT1 and GLUT9 expression, promoting uric acid excretion and lowering serum uric acid levels. Xanthine oxidase-IN-21 shows significantly hepatorenal protection activity. Xanthine oxidase-IN-21 can be used for the research of hyperuricemia^[1].

Xanthine oxidase-IN-21 (compound 5b) (0.1, 1, 10, 100, and 200 μM; 24 h) is non-cytotoxicity to HK-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Xanthine oxidase-IN-21 (compound 5b) (10-30 mg/kg, oral, daily, for 2 weeks) reduces uric acid levels, protects liver and kidney function, and ameliorates inflammation and fibrosis in Hyperuricemic mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

338.40

C₂₀H₂₂N₂O₃

O=C(OC)C1=CCC(OC)C2C1CC=C2CNC3=CC=C(C#N)C=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sun H, et al. Synthesis and biological evaluation of genipin derivatives as novel xanthine oxidase inhibitors for the anti-hyperuricemia and hepatorenal protection activity. Bioorg Chem. 2025;167:109279.  [Content Brief]